Antiangiogenic Therapy for Cancer: An Update

Al‐Husein, Belal; Abdalla, Maha; Trepte, Morgan; DeRemer, David L.; Somanath, Payaningal R.

doi:10.1002/phar.1147

Cited by 173 publications

(152 citation statements)

References 96 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…Back in 1970s, Dr. Judah Folkman has elegantly proposed the notion of anti-angiogenic therapy via cutting the blood supply off cancer cells and consequently depriving them of nutrients and eventually leading to their death [41]. Angiogenesis, the formation of new blood vessels, is known to play a central role in the progression of many solid tumors, like HCC [42] [43].…”

Section: S Persica Modulates the Essential Angiogenic Markersmentioning

confidence: 99%

<i>Salvadora persica</i> (Miswak): Antioxidant and Promising Antiangiogenic Insights

Al-Dabbagh¹,

Elhaty²,

Murali³

et al. 2018

AJPS

View full text Add to dashboard Cite

The use of plants to improve dental health and to promote oral hygiene has been practiced for centuries and persists in several communities throughout the world. Salvadora persica (Miswak) has a wide geographic distribution. The ancient Arabs had the habit of using it to whiten and polish the teeth. Here, we determined in vitro antioxidant activity, total phenols and flavonoids and evaluated antiproliferative activity of the extract of S. persica (Miswak). The MTT assay was used to estimate the antiproliferative activities of the extract against human hepatoma (HepG2) cancer cell line. Inhibition percentage of DPPH scavenging activity was dose-dependent and ranged from (30.7% ± 0.62) to (5.89% ± 0.98). The phenolic content was (2.7 ± 0.11) mg GAE/g while the flavonoid content was (2.70 ± 0.45) mg QE/g. Antiproliferative results of the extracts were found to be consistent with their antioxidant activity. Our extract also exhibited clear antiangiogenic activity. These findings introduce S. persica as the useful and novel potential anti-tumor agent for hepatocellular carcinoma (HCC) treatment.

show abstract

Section: S Persica Modulates the Essential Angiogenic Markersmentioning

confidence: 99%

<i>Salvadora persica</i> (Miswak): Antioxidant and Promising Antiangiogenic Insights

Al-Dabbagh¹,

Elhaty²,

Murali³

et al. 2018

AJPS

View full text Add to dashboard Cite

show abstract

“…These new vessels supply nutrients to the tumor, promoting cancer survival, growth, and dissemination. This process involves numerous factors; VEGF and its signaling are considered as one of the most important [14].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of factors associated with hypoxia and lipid metabolism in patients with colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is a neoplasia with high incidence and mortality rates. It had been suggested that the inflammatory response is an important CRC prognostic factor. The disordered and accelerated proliferation of neoplastic cells decreases the oxygen and nutrient supply, generating a microenvironment characterized by hypoxia, necrosis and inflammation. This study aimed to evaluate the impact of factors associated with hypoxia, such as HIF1A (hypoxia-inducible factor 1-alpha) and VEGF (vascular endothelial growth factor), and with lipid metabolism, including PPARG (peroxisome proliferator-activated receptor-gamma), LXRA (liver X receptor-alpha) and LXRB (liver X receptor-beta), on the overall survival (OS) of CRC patients. Methods: This was a cohort study of 101 patients with high-risk stage II-III (TNM) CRC located above the peritoneal reflection. They were treated between 1990 and 2004 at the AC Camargo Cancer Center. Immunohistochemical analyses of HIF1A, VEGF, PPARG, LXRA and LXRB protein expression were performed using tissue microarrays (TMAs). Results: There was an association between the presence of vascular invasion and the lack of VEGF expression (p = 0. 028) as well as with positive HIF1A expression and lymphatic invasion (p = 0.045). The 5-year and 10-year OS rates were 76.6% and 60.2%, respectively. Patients with PPARG-positive tumors had a higher OS (p = 0.018). There were no correlations between the positive expression of VEGF, HIF1A, LXRA or LXRB and OS. The Cox regression model demonstrated that the risk of death was 2.72-fold higher in patients with PPARG-negative tumors (95% CI = 1.08-6.85). Conclusion: The PPARG expression was an independent prognostic factor for CRC tumors and might be used for risk stratification to stage II and stage III CRC patients.

show abstract

“…The protein binds to VEGF-A, VEGF-B, and PlGF, inhibiting activation of VEGFR-1 and VEGFR-2 and thereby inhibiting angiogenesis [57,58]. Alibercept was approved as Zaltrap on 3 August 2012 for use in combination with a FOLFIRI (folinic acid, luorouracil, and irinotecan) chemotherapy regimen in adults with colorectal cancer [59], and has been shown to provide signiicant beneits in OS and PFS [60].…”

Section: Anti-vegf Medicationsmentioning

confidence: 99%

Anti-VEGF Therapy in Cancer: A Double-Edged Sword

Gardner¹,

Madu²,

Lü³

2017

Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a mitogen that plays a crucial role in angiogenesis and lymphangiogenesis. It is involved in tumor survival through inducing tumor angiogenesis and by increasing chemoresistance through autocrine signaling. Because of its importance in tumor formation and survival, several medications have been developed to inhibit VEGF and reduce blood vessel formation in cancer. Although these medications have proven to be efective for late-stage and metastatic cancers, they have been shown to cause side efects such as hypertension, artery clots, complications in wound healing, and, more rarely, gastrointestinal perforation and istulas. Current research in using anti-VEGF medication as a part of cancer treatments is focusing on elucidating the mechanisms of tumor resistance to VEGF medication, developing predictive biomarkers that assess whether a patient will respond to VEGF therapy and creating novel treatments and techniques that increase the eicacy of antiangiogenic medication. This chapter aims to review the role of VEGF in tumor angiogenesis and metastasis, the structure and function of VEGF and its receptors, and VEGF's role in cancer are discussed. Furthermore, tumor therapies targeting VEGF along with their side efects are presented and, inally, new directions in anti-VEGF therapy are considered along with the challenges.

show abstract

Antiangiogenic Therapy for Cancer: An Update

Cited by 173 publications

References 96 publications

<i>Salvadora persica</i> (Miswak): Antioxidant and Promising Antiangiogenic Insights

<i>Salvadora persica</i> (Miswak): Antioxidant and Promising Antiangiogenic Insights

Prognostic value of factors associated with hypoxia and lipid metabolism in patients with colorectal cancer

Anti-VEGF Therapy in Cancer: A Double-Edged Sword

Contact Info

Product

Resources

About

Antiangiogenic Therapy for Cancer: An Update

Cited by 173 publications

References 96 publications

&lt;i&gt;Salvadora persica&lt;/i&gt; (Miswak): Antioxidant and Promising Antiangiogenic Insights

&lt;i&gt;Salvadora persica&lt;/i&gt; (Miswak): Antioxidant and Promising Antiangiogenic Insights

Prognostic value of factors associated with hypoxia and lipid metabolism in patients with colorectal cancer

Anti-VEGF Therapy in Cancer: A Double-Edged Sword

Contact Info

Product

Resources

About

<i>Salvadora persica</i> (Miswak): Antioxidant and Promising Antiangiogenic Insights

<i>Salvadora persica</i> (Miswak): Antioxidant and Promising Antiangiogenic Insights